期刊文献+

血管肽酶抑制剂的研究与开发 被引量:2

Research and Development of Vasopeptidase Inhibitors
下载PDF
导出
摘要 血管肽酶抑制剂 (VPIs)能同时抑制血管紧张素转化酶和中性肽链内切酶 ,从而抑制肾素 血管紧张素 醛固酮系统和钠利尿肽的降解 ,促进血管舒张和尿钠排泄 ,发挥降低血压和改善心肾功能的作用。综述VPIs的作用机制及其产品用于高血压和充血性心衰的开发现状。 Vasopeptidase inhibitors(VPIs)show a dual inhibition of angiotensin-converting enzyme and neutral endopeptidase, and thus reduce the activity of the rennin-angiotensin-aldosterone system and the degradation of natriuretic peptides, potentiate the vasodilation and natriuresis, lower blood pressure and improve cardionephric function. The acting mechanism and development of VPIs for treatment of hypertension and congestive heart failure were reviewed.
作者 黄哲 王礼琛
出处 《药学进展》 CAS 2004年第5期214-217,共4页 Progress in Pharmaceutical Sciences
关键词 血管肽酶抑制剂 肾素 血管紧张素 醛固酮 高血压 充血性心力衰竭 Vasopeptidase inhibitor,Angiotensin-converting enzyme,Neutral endopeptidase,Hypertension,Congestive heart failure
  • 相关文献

参考文献21

  • 1Giuseppe M, Jean L R, Alber A. Vasopeptidase inhibitors:a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics[J]. Curr Opin Pharmacol, 2002, 2:131-141.
  • 2钱方毅.重视心力衰竭发病机制中的神经内分泌细胞因子系统的研究[J].中国循环杂志,2001,16(4):243-245. 被引量:44
  • 3Roberto C, John C B, Jean L R, et al. Vasopeptidase inhibitors:a new therapeutic concept in cardiovascular disease[J]. Circulation, 2001,104(10):1856-1862.
  • 4John M, Marc A. New therapeutic options in congestive heart failure: Part I[J]. Circulation, 2002, 105(4):2099-2106.
  • 5Weber M. Vasopeptidase inhibitor[J]. Lancet, 2001, 358:1525-1532.
  • 6Burnett J C. Vasopeptidase inhibition: a new concept in blood pressure management[J]. J Hypertens, 1999, 17(suppl 1):37-43.
  • 7Omapatrilat[J]. Pharmaprojects, 2003, a565.
  • 8Dougal R M, Hamid I, Amanda H G,et al. Effect of omapatrilat on systemic arterial functional in patients with chronic heart failure[J]. Am J Cardiol, 2001, 87(3):565-569.
  • 9Jean B, Jean C S. Vasopeptidase inhibitors:an emerging class of cardiovascular drugs[J]. Trands Pharmacol Sci, 2001, 22(3):106-109.
  • 10Jean L R, Duncan J S, Debra I, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure:impress random trial[J]. Lancet, 2000,356(9270): 615-620.

共引文献43

同被引文献13

  • 1张小平.血管紧张素转换酶抑制剂和血管肽酶抑制剂研究进展[J].食品与药品,2006,8(03A):15-18. 被引量:2
  • 2Merry LL, English CF, Christina E, et al. Alterations in cultured myocardial fibrohlast function following the development of left ventricular failure[J]. J Mol Cell Cardiol, 2006, 40:474-483.
  • 3Caroline C, Honglin I., Bobby Y, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus induced myocarditis [J]. Cardiovasc Pathol, 2006, 15:63-74.
  • 4Moe GW, Laurent G, Doumanovskaia L, et al. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure[J].J Card Fail, 2008,14(9):768-776.
  • 5Kostova E, Jovanoska E, Zafirov D, et al. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats[J]. Bratisl Lek Listy, 2005,106(12):407-411.
  • 6Dzielska-Olczak M. Omapatrilat-new drug for patients with hypertension and heart failure [J]. Pol Merkur Lekarski, 2005,19(112) :556-558.
  • 7Xu J, Carretero OA, Liu YH, et al. Dual inhibition of ACE and NEP provides greater cardio protection in mice with heart failure[J].Journal of Cardiac Failure, 2004, 10 (1):83-90.
  • 8Ziegel H, Ihaolovicova B, Briest W, et al. The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine treated rat hearts[J].Mol Cell Biochem, 2003, 247:61-68.
  • 9Lapointe NH, Blais C, Adam A, et al. Comparison of the effects of an angiotensin converting enzyme inhibi tot and a vasopeplidase inhibitor after myocardial in-farction in the rat [J].J Am Coll Cardiol, 2002,39: 1692-1 698.
  • 10Abassi ZA, Yahia A, Zeid S, et al. Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure [J]. Am J Physiol Heart Circ Physiol, 2005, 288: 722-728.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部